We refuse to stand still while bacterial infections continue to evade our control.
We are working urgently to help protect society from the consequences of extraintestinal pathogenic E. coli (ExPEC) and Staphylococcus aureus (S. aureus or staph) infections, including Methicillin-resistant S. aureus (MRSA) and other bacteria that cause bacterial lung infections, such as Pseudomonas aeruginosa.[1]
ExPEC and S. aureus are the two leading causes worldwide of invasive bacteraemia (presence of bacteria in the blood) and septicaemia (a life-threatening, uncontrolled inflammatory response to infection that may lead to organ failure and death), posing a serious threat to older adults with weakening immune systems.[1],[2]
In 2017, an estimated 48.9 million incident cases of sepsis and 11 million sepsis-related deaths were reported worldwide, representing almost 20% of all global deaths.[3]
Bacteria may develop antimicrobial resistance (AMR) or multidrug resistance (MDR), significantly increasing the severity of the infections, morbidity and mortality rates.[4], [5] AMR is one of the top ten threats to global health, according to the World Health Organization[6] and by 2050, AMR infections are predicted to kill more people than cancer.[7]
Structure of E.coli
As the primary cause of urinary tract infections, which can account for 25% of antibiotic prescriptions, ExPEC is considered a major driver behind the global AMR crisis [8],[9],[10]
In the fight against treatment resistance, both vaccines and therapeutics have a vital role to play, alongside the development of new antibiotics, better diagnostics and coordinated strategies to improve the use of antibiotics.[7],[11] That is why we prioritise developing novel solutions to reduce the devastating consequences of infection, dependency on antibiotics and the risk of AMR and MDR.
Follow Us
CP-187341